National Fibromyalgia Association Hails FDA Approval of Cymbaltaź for the
Management of Fibromyalgia as “Important Step” for Patient Care
ANAHEIM, Calif. (June 17, 2008)---In a statement issued yesterday by National Fibromyalgia Association president and founder Lynne Matallana, the FDA approval of Cymbaltaź for the management of fibromyalgia was hailed as “another important step in the efforts to ensure that people with fibromyalgia will have the availability of effective medications to help reduce the chronic, widespread pain of this life-altering disorder.”
Cymbalta is the first serotonin-norepinephrine reuptake inhibitor with proven efficacy for reducing pain in patients with fibromyalgia. The fibromyalgia indication represents the second FDA-approved use for Cymbalta for a pain disorder.
Cymbalta is also the second FDA-approved drug for fibromyalgia. Last June, the FDA approved Lyrica (pregabalin), as the first drug to treat fibromyalgia.
Matallana, who was diagnosed with fibromyalgia in 1995 before founding the NFA two years later, said, “The FDA approval of the second drug to treat fibromyalgia helps to continue to improve public and medical awareness, and gives the patients hope for additional treatments that will be effective.”
Click here to read a consumer update from the U.S. Food and Drug Administration.
ABOUT THE NFA:
The National Fibromyalgia Association is a nonprofit 501(c)(3) organization whose mission is to develop and execute programs dedicated to improving the quality of life for people with fibromyalgia by increasing the awareness of the public, media, government and medical communities. The NFA publishes a quarterly magazine, Fibromyalgia AWARE and hosts an award-winning website at http://www.FMaware.org